Neuronetics appoints Robert Greene as SVP Sales with 200,000 RSUs
STIM•Neuronetics has appointed Robert Greene as Senior Vice President of Sales effective June 1, 2026, drawing on his extensive healthcare and medical technology experience. The board granted Greene 200,000 restricted stock units vesting in four equal annual installments under NASDAQ Listing Rule 5635(c)(4).
1. Appointment of Senior Vice President Sales
Neuronetics has named Robert Greene Senior Vice President Sales effective June 1, 2026. Greene will oversee the company’s commercial operations and drive sales strategy for the NeuroStar® Advanced Therapy System and related treatment services.
2. Inducement Grant Details
In connection with his hire, the Compensation Committee approved an inducement grant of 200,000 restricted stock units. These units vest in four equal annual installments on each anniversary of the grant date, subject to continued employment and capitalization adjustments under NASDAQ Listing Rule 5635(c)(4).
3. Professional Background
Robert Greene brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology sectors. His background includes managing capital equipment and service sales teams, positioning him to expand market penetration for Neuronetics’ neurohealth products.
